How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,035 results for

Hypertension Evaluation Labs

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Diagnosis & Assessment of Hypertension - Lab Tests

Diagnosis & Assessment of Hypertension - Lab Tests V. Routine and Optional Laboratory Tests for the Investigation of Patients with Hypertension | Hypertension Canada Guidelines Subgroup Members: Brian Penner, MD; Ellen Burgess, MD; Praveena Sivapalan, MD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C. Harris, MD MHSc; Kerry McBrien, MD MPH; Sonia Butalia (...) of hypertension management, tests (including those for electrolyte, creatinine, and fasting lipids) should be repeated with a frequency reflecting the clinical situation (Grade D). Follow-up lab testing may be indicated to monitor for adverse effects of antihypertensive treatment, as surveillance for the development of end-organ damage and/or to re-stratify cardiovascular risk. The need for such testing differs across hypertensive patients and, in the absence of specific studies to define the optimal testing

2018 Hypertension Canada

2. Hypertension Evaluation Labs

Hypertension Evaluation Labs Hypertension Evaluation Labs Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Hypertension Evaluation Labs (...) Hypertension Evaluation Labs Aka: Hypertension Evaluation Labs , Hypertension Diagnostic Testing From Related Chapters II. Labs: General for All Patients ( or minimum) g lipid profile Non- g may be sufficient initially However, high g serum levels (with low ) may suggest Basic Metabolic Panel (Chem8, SMA7) g is preferred (esp. if non- g is abnormal) Consider primary if (even borderline low) With calculated (GFR) increased in , , renal parenchymal disease (BUN) III. Labs: Optional Studies (as indicated

2018 FP Notebook

3. Diuretic Effect Evaluation of Petroselinum Crispum (Parsley) in Hypertensive Patients

Diuretic Effect Evaluation of Petroselinum Crispum (Parsley) in Hypertensive Patients Diuretic Effect Evaluation of Petroselinum Crispum (Parsley) in Hypertensive Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Diuretic Effect Evaluation of Petroselinum Crispum (Parsley) in Hypertensive Patients (DEEP) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03468361 Recruitment Status : Enrolling by invitation First Posted : March 16, 2018 Last Update Posted : January 29, 2019 Sponsor: University

2018 Clinical Trials

4. Chronic Sleep Deprivation Among the Poor: A Lab-in-the-field Approach

Deprivation Among the Poor: A Lab-in-the-field Approach The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03322358 Recruitment Status : Recruiting First Posted : October 26, 2017 Last Update Posted : February 21, 2019 See Sponsor (...) Chronic Sleep Deprivation Among the Poor: A Lab-in-the-field Approach Chronic Sleep Deprivation Among the Poor: A Lab-in-the-field Approach - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Chronic Sleep

2017 Clinical Trials

5. CADence Performance as a Rule-Out Modality in Long Beach Veterans Administration Heart Catheterization Lab Patients

of saved studies (100). Please remove one or more studies before adding more. CADence Performance as a Rule-Out Modality in Long Beach Veterans Administration Heart Catheterization Lab Patients (SOLDIER) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details (...) CADence Performance as a Rule-Out Modality in Long Beach Veterans Administration Heart Catheterization Lab Patients CADence Performance as a Rule-Out Modality in Long Beach Veterans Administration Heart Catheterization Lab Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2017 Clinical Trials

6. Hypertension Evaluation Labs

Hypertension Evaluation Labs Hypertension Evaluation Labs Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Hypertension Evaluation Labs (...) Hypertension Evaluation Labs Aka: Hypertension Evaluation Labs , Hypertension Diagnostic Testing From Related Chapters II. Labs: General for All Patients ( or minimum) g lipid profile Non- g may be sufficient initially However, high g serum levels (with low ) may suggest Basic Metabolic Panel (Chem8, SMA7) g is preferred (esp. if non- g is abnormal) Consider primary if (even borderline low) With calculated (GFR) increased in , , renal parenchymal disease (BUN) III. Labs: Optional Studies (as indicated

2015 FP Notebook

7. Gamechanger? Is Spironolactone the Magic Bullet for Resistant Hypertension?

or thiazide-like diuretic, is associated with a poor prognosis and poses a unique challenge to physicians. It is estimated that at least one in 10 patients with hypertension are drug-resistant, [1]. The PATHWAY-2 trial is a recent, potentially groundbreaking study that evaluated the use of spironolactone versus placebo and other anti-hypertensives to determine whether it is an optimal, effective treatment for rHTN. The underlying pathophysiology of rHTN is poorly understood, but is hypothesized (...) Gamechanger? Is Spironolactone the Magic Bullet for Resistant Hypertension? Gamechanger? Is Spironolactone the Magic Bullet for Resistant Hypertension? – Clinical Correlations Search Gamechanger? Is Spironolactone the Magic Bullet for Resistant Hypertension? November 9, 2016 8 min read By Amar Parikh, MD Peer Reviewed Welcome to Gamechangers, a series that takes a critical look at the latest in medical literature to answer one important question: would the results of this article change my

2016 Clinical Correlations

8. Evaluation and Management of Testosterone Deficiency

Evaluation and Management of Testosterone Deficiency 1 Executive Summary Testosterone testing and prescriptions have nearly tripled in recent years; however, it is clear from clinical practice that there are many men using testosterone without a clear indication. 1-3 Some studies estimate that up to 25% of men who receive testosterone therapy do not have their testosterone tested prior to initiation of treatment. 2, 3 Of men who are treated with testosterone, nearly half do not have (...) of interest and author/staff contribu- tions appear at the end of the article. © 2018 by the American Urological Association American Urological Association (AUA) EVALUATION AND MANAGEMENT OF TESTOSTERONE DEFICIENCY: AUA GUIDELINE John P. Mulhall, MD; Landon W. Trost, MD; Robert E. Brannigan, MD; Emily G. Kurtz, MD; J. Bruce Redmon, MD; Kelly A. Chiles, MD MSc; Deborah J. Lightner, MD; Martin M. Miner, MD; M. Hassan Murad, MD, MPH; Christian J. Nelson, PhD; Elizabeth A. Platz, ScD, MPH; Lakshmi V

2018 American Urological Association

9. Middle Aged Woman with Asystolic Cardiac Arrest, Resuscitated: Cath Lab?

Middle Aged Woman with Asystolic Cardiac Arrest, Resuscitated: Cath Lab? Dr. Smith's ECG Blog: Middle Aged Woman with Asystolic Cardiac Arrest, Resuscitated: Cath Lab? Sunday, October 20, 2013 A middle-age woman with h/o hypertension was found down by her husband. Medics found her apneic and pulseless, began CPR, and she was found to be in asystole. With ventilations and epinephrine, she regained a pulse. She was never seen to be in ventricular fibrillation and was never defibrillated. She (...) depression c/w posterior MI to be a STEMI equivalent. Finally, they also allow one to consider elevation in aVR to be a STEMI equivalent providing that it is associated with multilead ST depression " In other words, this ECG, in the right clinical scenario, qualifies for a STEMI-equivalent and is an indication for activating the cath lab. I am not in complete agreement with the recommendation for aVR, because: 1) diffuse subendocardial ischemia is more likely to have non-ACS causes than traditional STEMI

2013 Dr Smith's ECG Blog

10. Hypertensive Urgency: Considerations for Management

on the floor & arm supported) (Please refer to Hypertension Canada’s Blood Pressure Measurement Information Sheet for more detailed guidance). ? Obtain medical history & current medication list (prescription, OTC, recreational) ? Physical exam - focus on any signs of target organ damage (e.g. shortness of breath, chest pain, numbness/weakness) ? Lab tests & investigations may be required (e.g. CBC, ECG, urinalysis, renal function; ultrasound for aortic dissection if very high BP) ? Hypertensive urgency (...) , Calcium Channel Blocker Chronic Kidney Disease ACE Inhibitor (or ARB) WHAT ARE THE FOLLOW-UP & MONITORING PARAMETERS FOR HYPERTENSIVE URGENCY? 2-11 ? The patient should be observed for a few hours to confirm that they are stable/improving & asymptomatic ? Once stable, the patient can be sent home with close follow-up (every 1-2 days) involving: - Evaluation for signs of hypertension or hypotension - Attainment of BP goals with the help of antihypertensives and lifestyle interventions (e.g. low salt

2014 RxFiles

11. Evaluation of Abnormal Liver Chemistries

article. Liver chemistries that are commonly ordered in comprehensive metabolic profi les are indirect markers of hepatobiliary disease. Th ey are not true measures of hepatic function and thus are best referred Table 1 . Recommendations 1. Before initiation of evaluation of abnormal liver chemistries, one should repeat the lab panel and/or perform a clarifying test (e.g., GGT if serum alkaline phosphate is elevated) to con? rm that the liver chemistry is actually abnormal. (Strong recommendation (...) the likelihood of hepatomegaly being present but in and of itself does not imply an enlarged liver is present ( 76,77 ). A fi rm Before initiation of evaluation of abnormal liver chemistries, one should repeat the lab panel and/or perform a clarifying test (e.g., GGT if serum alkaline phosphate is elevated) to confi rm that the liver chemistry is actually abnormal. Th e initial history should assess risk factors for liver diseases including viral hepatitis, meta- bolic liver disease, exposures to toxins

2017 American College of Gastroenterology

12. Improving proteinuria screening with mailed smartphone urinalysis testing in previously unscreened patients with hypertension: a randomized controlled trial. (PubMed)

, randomized trial at 55 primary care clinic sites in the Geisinger Health System to evaluate the effectiveness of a strategy using home smartphone urinalysis test (Dip.io) to complete proteinuria screening in previously unscreened non-diabetic patient portal users with hypertension. All patients received an educational letter and a standing urinalysis lab order, and then were randomized to control (usual care) or intervention. Intervention arm participants were invited to complete proteinuria screening (...) a home urinalysis smartphone test increased proteinuria screening rates in previously unscreened patients with hypertension and may be useful in increasing rates of proteinuria screening compliance. Future studies should evaluate use of home testing kits to screen for and confirm albuminuria, and determine whether improving early detection of kidney disease can improve future kidney health.Clinical Trial Registry: NCT03470701 (First posted 3/20/2018) https://clinicaltrials.gov/ct2/show/NCT03470701

Full Text available with Trip Pro

2019 BMC Nephrology

13. Tadalafil - Pulmonary Hypertension

Tadalafil - Pulmonary Hypertension 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 10 November 2016 EMA/803097/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Tadalafil Generics International non (...) Suspect Adverse Reaction Report Form Cl Clearance CLcr or CrCl Creatinine clearance Cmax maximum plasma concentration CMH test Haenszel test CO Cardiac output. CoA Certificate of Analysis CP Cerebral palsy CPPs Critical process parameters CQAs Control quality attributes CRO Certified Research Organisation CSF Cerebrospinal fluid CTEPH Chronic thromboembolic pulmonary hypertension CV Coefficient of Variation CW Clinical worsening CYP450 cytochrome P450 DAP Drug Analysis Print DDI Drug-drug interactions

2017 European Medicines Agency - EPARs

14. Pediatric Pulmonary Hypertension

Society, a panel of experienced clinicians and clinician-scientists was assembled to review the current literature and to make recommendations on the diagnosis, evaluation, and treatment of pediatric pulmonary hypertension. This publication presents the results of extensive literature reviews, discussions, and formal scoring of recommendations for the care of children with pulmonary hypertension. (Circulation. 2015;132:2037-2099. DOI: 10.1161/CIR.0000000000000329.) Key Words: AHA Scientific Statements (...) on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; and the American Thoracic Society Downloaded from http://ahajournals.org by on March 27, 20192038 Circulation November 24, 2015 1. Introduction 1.1. Rationale and Goals This guidelines document addresses approaches to the evalu- ation and treatment of pulmonary hypertension (PH) in chil- dren, defined as a resting mean pulmonary artery pressure (mPAP) >25 mm Hg beyond

Full Text available with Trip Pro

2015 American Heart Association

15. Pediatric Pulmonary Hypertension: ATS/AHA Clinical Practice Guidelines

Heart Association and American Thoracic Society, a panel of experienced clinicians and clinician-scientists was assembled to review the current literature and to make recommendations on the diagnosis, evaluation, and treatment of pediatric pulmonary hypertension. This publication presents the results of extensive literature reviews, discussions, and formal scoring of recommendations for the care of children with pulmonary hypertension. (Circulation. 2015;132:00-00. DOI: 10.1161/CIR.0000000000000329 (...) / Downloaded from by guest on March 15, 2016 http://circ.ahajournals.org/ Downloaded from 2 Circulation November 24, 2015 1. Introduction 1.1. Rationale and Goals This guidelines document addresses approaches to the evalu- ation and treatment of pulmonary hypertension (PH) in chil- dren, defined as a resting mean pulmonary artery pressure (mPAP) >25 mm Hg beyond the first few months of life. This document focuses on childhood disorders of PH result- ing from pulmonary vascular disease (PVD) and includes PH

2015 American Thoracic Society

16. Evaluation Of Clinical Efficacy And Immunogenicity Of Eritromax® Produced By Lab Blau Pharmaceutical S / A. Compared To The Product Eprex®, Produced By The Laboratory Janssen-Cilag, In Patients With Anemia Secondary To Chronic Kidney Disease

Evaluation Of Clinical Efficacy And Immunogenicity Of Eritromax® Produced By Lab Blau Pharmaceutical S / A. Compared To The Product Eprex®, Produced By The Laboratory Janssen-Cilag, In Patients With Anemia Secondary To Chronic Kidney Disease Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results (...) information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2012 Clinical Trials

17. Diagnosis, Evaluation and Follow-up of Asymptomatic Microhematuria (AMH) in Adults

Diagnosis, Evaluation and Follow-up of Asymptomatic Microhematuria (AMH) in Adults Microhematuria: Asymptomatic - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online (...) Managers' Network (PMN) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Diagnosis, Evaluation and Follow-up of Asymptomatic Microhematuria (AMH) in Adults (2016) Published 2012; Reviewed and Validity Confirmed 2016 Diagnosis, Evaluation and Follow-up of Asymptomatic Microhematuria (AMH) in Adults discusses proper evaluation of such patients, including use of cystoscopy and imaging, and follow up for patients with persistent or recurrent symptoms following a negative

2016 American Urological Association

18. Management of Hypertension (HTN) in Primary Care

blood pressure (SBP) >140 mmHg or a diastolic blood pressure (DBP) of >90 mmHg. Prehypertension is classified as SBP 120-139 or DBP 80-89. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) went on to further classify hypertension into stages [1] (Stage 1: SBP 140- 159 mmHg or DBP 90-99; Stage 2: SBP >160 mmHg or DBP >100 mmHg), though the use of these stages has begun to be phased out. Hypertension is usually (...) , herbal remedies, and dietary supplements, some of which may raise blood pressure or interfere with the effectiveness of antihypertensive medications 10. History of alcohol and illicit drug use (especially cocaine and other stimulants) 11. Psychosocial and environmental factors (e.g., family situation, employment status and working conditions, level of comprehension) that may influence hypertension controlOctober 2014 Page 24 of 135 A physical exam should include an evaluation for signs of secondary

2014 VA/DoD Clinical Practice Guidelines

19. Cath lab activated. What do you think? (#2)

on this. What the medics did not see is that the S-waves are cut off. You can see that they are very wide where they are cut off, and if you project them down they will be very deep S-waves. On arrival, we cancelled the cath lab activation and started a high dose nitroglycerin drip, up to 200 mcg/min. We recorded this ED ECG: This is similar to the above, but does not cut off the S-waves, which you can now see are very deep. The patient had pulmonary edema due to severe hypertension, and he ruled out (...) Cath lab activated. What do you think? (#2) Dr. Smith's ECG Blog: Cath lab activated. What do you think? (#2) Saturday, April 16, 2011 This 45 year old male called 911 for increasing SOB and CP over 2 weeks. His BP was 220/150. The medics did a prehospital ECG, shown here. They tried to activate the cath lab, but the message did not get through. There are several worrisome findings: Upright T-wave in V1, large T-wave with ST elevation in V1-V4. The medics activated the cath lab based

2011 Dr Smith's ECG Blog

20. Abstract 79: Chronic and Acute Hypertension in Ischemic Stroke Are Distinct Markers of Impaired Collateral Circulation. (PubMed)

of Stroke III angiography core lab prospectively evaluated collateral circulation utilizing the ASITN scale prior to endovascular therapy. We used these data to discern the relationship of clinical and imaging markers of premorbid HTN with acute, serial BP measures and collaterals.Collaterals at angiography were graded in 276/331 (83%) subjects. Higher initial BP was associated with impaired collateral status, driven by diastolic BP (ASITN 0-1: mean 88.9 ± 23.5 mmHg (n=70); 2: 82.7 ± 18.5 mmHg (n=106 (...) Abstract 79: Chronic and Acute Hypertension in Ischemic Stroke Are Distinct Markers of Impaired Collateral Circulation. Acute blood pressure (BP) elevation in acute ischemic stroke (AIS) is common, yet the link with collateral circulation remains elusive due to lack of longitudinal data on premorbid hypertension (HTN) and serial BP changes within an individual. Precision medicine for AIS and management of HTN requires an understanding of collateral circulation.The Interventional Management

2018 Stroke

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>